Education
About Us
Working with TipRanks
Follow Us
Candel Therapeutics (CADL)
NASDAQ:CADL
CADL Stock Chart & Stats
Day’s Range― - ―
52-Week Range$3.79 - $14.60
Previous CloseN/A
Volume524.53K
Average Volume (3M)746.40K
Market Cap
$300.28M
Enterprise Value$168.19M
Total Cash (Recent Filing)$100.69M
Total Debt (Recent Filing)$8.34M
Price to Earnings (P/E)―
Beta0.28
Next Earnings
Nov 06, 2025EPS Estimate
-0.18Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.09
Shares Outstanding54,895,100
10 Day Avg. Volume742,368
30 Day Avg. Volume746,399
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market Cap0.56
Enterprise Value/Revenue168.19
Enterprise Value/Gross Profit-172.15
Enterprise Value/Ebitda-4.70
Forecast
1Y Price Target
$19.67Price Target Upside249.38% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering6
Bulls Say, Bears Say
Bulls Say
Efficacy And ApprovalCAN-2409's efficacy in reducing disease recurrence by 30% and its robust secondary endpoints are believed to provide sufficient grounds for approval.
Market PotentialCAN-2409 is positioned as a versatile immunotherapy for multiple billion-dollar indications, with prostate cancer as the lead revenue driver.
Regulatory AdvancementsCAN-2409 has received Regenerative Medicine Advanced Therapy and Fast Track designations from the FDA for the treatment of newly diagnosed localized prostate cancer.
Bears Say
Funding RequirementsAdditional funding will be required for pursuing Phase 3 trials for CAN-2409 in non-small cell lung cancer and pancreatic cancer.
Integration ChallengesThere are lingering questions about the optimal integration of CAN-2409 into current treatment paradigms and the durability of disease-free survival improvements.
Candel Therapeutics News
CADL FAQ
What was Candel Therapeutics’s price range in the past 12 months?
Candel Therapeutics lowest stock price was $3.79 and its highest was $14.60 in the past 12 months.
What is Candel Therapeutics’s market cap?
Candel Therapeutics’s market cap is $300.28M.
When is Candel Therapeutics’s upcoming earnings report date?
Candel Therapeutics’s upcoming earnings report date is Nov 06, 2025 which is in 28 days.
How were Candel Therapeutics’s earnings last quarter?
Candel Therapeutics released its earnings results on Aug 14, 2025. The company reported -$0.09 earnings per share for the quarter, beating the consensus estimate of -$0.164 by $0.074.
Is Candel Therapeutics overvalued?
According to Wall Street analysts Candel Therapeutics’s price is currently Undervalued.
Does Candel Therapeutics pay dividends?
Candel Therapeutics does not currently pay dividends.
What is Candel Therapeutics’s EPS estimate?
Candel Therapeutics’s EPS estimate is -0.18.
How many shares outstanding does Candel Therapeutics have?
Candel Therapeutics has 54,895,100 shares outstanding.
What happened to Candel Therapeutics’s price movement after its last earnings report?
Candel Therapeutics reported an EPS of -$0.09 in its last earnings report, beating expectations of -$0.164. Following the earnings report the stock price went down -5.625%.
Which hedge fund is a major shareholder of Candel Therapeutics?
Currently, no hedge funds are holding shares in CADL
Candel Therapeutics Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$19.67 (249.38% Upside)
$19.67 (249.38% Upside)
Blogger Sentiment
Bullish
CADL Sentiment 100%
Sector Average 72%
Sector Average 72%
Hedge Fund Trend
Decreased
By 2.1M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Neutral
Last 7 Days ▲ 0.7%
Last 30 Days ▼ 7.0%
Last 30 Days ▼ 7.0%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-12.44%
12-Months-Change
Fundamentals
Return on Equity
-55.18%
Trailing 12-Months
Asset Growth
300.11%
Trailing 12-Months
Company Description
Candel Therapeutics
Candel Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the development immunotherapies for the cancer patients. The company develops CAN-2409, which is in Phase II clinical trails for the treatment of pancreatic cancer; Phase III clinical trials for the treatment of prostate cancer; and Phase II clinical trials for the treatment of lung cancer, as well as has completed Phase Ib/II clinical trials for the treatment of high-grade glioma. It also develops CAN-3110, which is in Phase I clinical trials for the treatment of recurrent glioblastoma. The company was formerly known as Advantagene, Inc. and changed its name to Candel Therapeutics, Inc. in November 2020. The company was incorporated in 2003 and is based in Needham, Massachusetts.
CADL Stock 12 Month Forecast
Average Price Target
$19.67
▲(249.38% Upside)
Technical Analysis
Tonix Pharma
―
Quantum-Si
―
Humacyte
―
Monte Rosa Therapeutics
―
Inhibrx Biosciences Inc
―
Ownership Overview
19.77% Insiders
16.80% Mutual Funds
11.32% Other Institutional Investors
46.21% Public Companies and
Individual Investors